Browsing "Medicine" by Author Eadie, L.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
PreviewIssue DateTitleAuthor(s)
2016ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell linesEadie, L.; Hughes, T.; White, D.; Eaves, C.
2016ABCB1 overexpression predicts outcome of CML patients undergoing first-line imatinib treatmentEadie, L.; Hughes, T.; White, D.; New Directions in Leukaemia Research 2016 Meeting (NDLR) (16 Mar 2016 - 19 Mar 2016 : Noosa, QLD)
2018ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cellsEadie, L.; Dang, P.; Goyne, J.; Hughes, T.; White, D.; Maga, G.
2008Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsHiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
2013Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Eadie, L.; Saunders, V.; Hughes, T.; White, D.
2019High risk genomic alterations identified at the time of diagnosis are strongly associated with MRD and subsequent poor outcomes in AYA ALL patients treated on a pediatric inspired chemotherapy regimenYeung, D.; Greenwood, M.; Rehn, J.; Heatley, S.; McClure, B.; Eadie, L.; Breen, J.; Schutz, C.; Trahair, T.; Wei, A.; Dalla-Pozza, L.; Sutton, R.; Bradstock, K.; Osborn, M.; White, D.; American Society of Hematology Annual Meeting (ASH) (7 Dec 2019 - 10 Dec 2019 : Orlando, CA)
2014Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinibEadie, L.; Hughes, T.; White, D.
2013Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsWhite, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.